Phaseline

Companies › Triple Hair

Triple Hair: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TH07
Fixed combination of 5-alpha reductase inhibitor (finasteride), alpha-adrenergic agonist (
SRD5A2, PTGFRPhase 3Androgenic AlopeciaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07435012TH07Phase 3Androgenic AlopeciaImmunologyDec 2027

Targets

SRD5A2 (1) PTGFR (1)

Companies with the same targets

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair SpyGlass Pharma Glaukos YS Life Science Santen Pharmaceutical

Companies built like this

Biopharma Plasma Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Infant Bacterial Therapeutics Aresus Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.